Background. Blood pressure (BP) control immediately after renal transplantation is poorly understood, with patients experiencing both high and low BP levels. Donor kidneys lack the ability to autoregulate their blood flow, meaning high pressures are directly translated to the graft endothelium, whereas reduced perfusion may augment ischemic injury. We hypothesize that early BP control may therefore influence the early alloimmune response.
Perioperative hypertension (PHT) is associated with a number of adverse outcomes (1-3). The incidence of PHT is approximately 3% in all patients after general surgery. A higher incidence is seen in those with preexisting hypertension or after intracranial or vascular surgery (2) . Although 60% to 80% of patients are hypertensive within 1 year of renal transplantation (4, 5) , blood pressure (BP) control immediately after renal transplantation is poorly understood.
Hypertension contributes to patient morbidity and mortality (6) , and PHT may also have deleterious effects on the renal allograft. Unlike native kidneys, donor tissue lacks the ability to autoregulate blood flow (7) , resulting in systemic pressures being directly translated to the allograft endothelium. Low perfusion pressures may conceivably potentiate ischemic injury and delay graft function. On the other hand, biomechanical activation of endothelium exposed to high shear forces results in increased leukocyte adhesion, the production of chemoattractants, and the expression of alloantigens (8 -10) . This study aims to document the incidence of PHT and examine the effect of perioperative BP on early allograft outcomes after renal transplantation.
MATERIALS AND METHODS

Study Population
Three hundred sixty-five patients undergoing primary cadaveric renal transplantation (CD-1) at The Queen Elizabeth Hospital, Adelaide, Australia, between January 1, 1990, and January 1, 2000 were reviewed. During this period, transplantation was conducted under the same surgical team using the same postoperative management protocols. Patients with primary graft failure, death without graft function, or graft loss because of technical complications were excluded (nϭ25). All CD-1 patients receiving cyclosporine, mycophenolate, or azathioprine and/or prednisolone as their starting immunosuppression on an intention-to-treat basis were identified (nϭ276) and formed the primary study group. In this protocol (11) , cyclosporine (5 mg/kg/day with diltiazem or 8 mg/kg/day without diltiazem), mycophenolate (2 g/day), or azathioprine (2 mg/kg/day) was first given orally 6 to 8 hr after transplantation. Even in patients with delayed graft function (DGF), cyclosporine was not withheld during the study period (initial 53 hr). Every patient received an intravenous bolus dose of 1 g of methylprednisolone before surgery and 500 mg on the following morning. Only CD-1 patients sensitized to panel-reactive lymphocytotoxic antigens (peak PRAϾ50%) with a positive T-or B-cell crossmatch or steroid-dependent patients received oral prednisolone (30 mg/day), beginning from day 2. All patients received a similar general anesthetic, were catheterized, and received similar postoperative protocol-driven analgesia.
Assessment of BP
Preoperative BP levels were calculated from the mean of two measurements taken by ward and anesthetic staff. Systolic BP recordings were obtained at 10-min intervals during surgery (intraoperative BP) and at 15-min intervals while in recovery. After the return to the ward, the BP for each patient was recorded hourly until stable and subsequently every 2 hr for 53 hr in total after the time of reperfusion. BP, measured from graft reperfusion until 50 hr after surgery, was considered as area under the curve and standardized by time of recordings (12) and expressed as standardized postperfusion blood pressure (BP pp ).
All patients received diltiazem at a dose of 60 mg three times daily commencing 4 to 8 hr after surgery, with the exception of aboriginal patients who did not receive diltiazem. The use of drugs with antihypertensive effects during the study period (excluding diltiazem and loop diuretics) was recorded. As a protocol, antihypertensive therapies were discontinued in the perioperative period except for patients on ␤-blockers who continued their therapy. Perioperative hydration was standardized with continuous measurement of central venous pressure and urine output.
Transplant Variables
Transplant records were obtained from a common database. Sixteen categorical variables (scored 0 or 1) were determined: donor gender, recipient gender, recipient ethnicity, primary renal disease, type of dialysis, recipient history of smoking, vascular events, diabetes and preexisting hypertension, sensitization (PRAϾ50%), the use of oral prednisolone, the use of azathioprine or mycophenolate, the use of diltiazem, and the use of antihypertensive therapy after surgery, and the presence of donor hypertension (BPϾ140/90 mm Hg) or hypotension (Ͻ70 mm Hg systolic) in the 48 hours before organ retrieval. Eight continuous variables were established: donor age; recipient age; recipient weight; ischemic time; duration of operation; HLA-A, -B, and -DR matching (scored 0 -6); and fluid received during surgery (colloid, crystalloid, and transfusion). In addition, the presence of donor hypertension (BP Ͼ140/90 mm Hg) or hypotension (Ͻ70 mm Hg systolic) in the 48 hr before to organ retrieval was recorded. A previous history of donor hypertension was recorded when available. As a crude surrogate for donor hypertension, cadaveric donors older than 35 years of age who had a vascular event as the primary cause of death were identified.
Outcome Measures
Transplantation records of all 276 patients were examined for the presence of allograft rejection. Acute rejection was defined as biopsyproven or clinical rejection occurring within 28 days of transplantation. If a biopsy was not performed, clinical rejection was retrospectively identified by a sustained rise of more than 10% from the predicted serum creatinine level, responsive to adjunctive immunosuppressive therapy. DGF was defined by the need for dialysis after transplantation.
Statistical Tests
Continuous variables were expressed as mean Ϯ SD. Where appropriate, univariate relations between variables were determined by simple correlation or linear (least squares) regression; differences between continuous variables were analyzed by t test and categorical variables by chi-square analysis and Fisher exact test.
Potential predictors of acute rejection (full model) were considered in a multivariate Cox regression; the final model variables were determined by sequential penalized likelihood (Akaike information criterion) (13) . Cox model parameter estimates are reported as hazard ratios which, being rates, are not to be (literally) interpreted as risk ratios. Categorical ("cut-point") analysis of continuous variables was not primarily used except when testing for first-order interactions and initial bivariate screening was not performed (14) . Attention was directed to the question of model selection with correlated variables, a ubiquitous problem in data sets such as these, and the potential effect of multicolinearity (variance inflation factor Ͻ10 and condition number Ͻ15) was carefully assessed (15) . Functional form (in particular, nonlinearity) of continuous variables in the final model was checked graphically using martingale residual plots and formally by parametric (fractional polynomials) and nonparametric methods (cubic smoothing splines) (16) . Cox model performance was assessed using (i) residual plots, (ii) global proportional hazards and goodness-of-fit tests, and (iii) Harrell's c-statistic (comparable to receiver operating characteristic [ROC] curve with an acceptable discrimination area Ͼ0.5) (17) .
Patient heterogeneity (frailty) was also determined within the Cox analysis (18) . A frailty model is a random effects model for time variables for which the random effect has a (latent) multiplicative effect on the hazard. Frailty addresses unexplained variability in terms of omitted covariate(s); thus, if frailty is ignored, a potentially biased estimation of covariate effect will be observed. The implications of a "frailty effect" seem not to hve been previously addressed in the transplant literature.
Predictors of DGF were identified by logistic regression, and predictor effect was parameterized as odds ratios using logistic regression and risk ratios using a generalized linear model (GLM) with Bernoulli family and log link (19) . Generalized linear models are a wider class of the classical linear model, retaining the concept of additive explanatory effects but providing extensions of the distributional assumptions of the response variable (within the exponential family; as counts, binary, proportions, and positive-valued distributions) and allowing a transformed scale on which the explanatory effects combine, by virtue of a monotonic and differential link function connecting the linear predictor with fitted values (19) The problem of having, within the same data set, an outcome measure (DGF) as a predictor for acute rejection and potentially simultaneously determined with acute rejection, was addressed using an instrumental variables approach (20) applied to logistic regression (such estimation not being available for Cox regression), with rejection as the determinate outcome (21) . Performance of Cox and logistic regression are known to be similar for short follow-up times (22) . DGF was modeled as an endogenous variable with the predictors of DGF used as instruments (uncorrelated with the determinate outcome) and the predictors of rejection being considered as exogenous. The theory behind this determination is such: the instrumental variables have a substantial effect upon DGF but not on acute rejection; the variation in DGF induced by (the variation in) the instruments is then used to study the effect of DGF on acute rejection. The utility of the instrumental approach versus conventional logistic regression was tested with the Hausman specification and Smith-Blundell tests (23) . The performance of conventional logistic regression was assessed by indices of calibration (HosmerLemeshow chi-square statistic; PϾ0.10) and discrimination (ROC curve area Ͼ0.7) (24).
RESULTS
Demographics
Two hundred seventy-six patients received cyclosporinbased immunosuppression after successful transplantation. All patients were reviewed in this study. Patient characteristics are shown in Table 1 .
BP Recordings
The mean BP before surgery was 156Ϯ23 (range,
The systolic BP fell at the induction of anesthesia by a mean of 30Ϯ10 mm Hg. This fall was more marked in patients with preoperative hypertension (Fig. 1) . At the time of reperfusion, mean systolic BP was 128Ϯ17 (range, 80 -180) mm Hg. After cessation of anesthetic, BP measurements returned to preoperative levels (mean systolic 156Ϯ27 mm Hg, range 95-230; mean diastolic 85Ϯ16 mm Hg, range 50 -150). The rise in BP after cessation of anesthetic was greatest in patients who were hypertensive before surgery (Fig. 1) . BP levels were highest in the period immediately after surgery, then falling by approximately 10 mm Hg (mean systolic and diastolic) to a nadir 12 to 15 hr after transplantation. However, by 50 hr after reperfusion, the mean BP levels had risen again to preoperative levels (Fig. 2) . This pattern was independent of graft function or the subsequent occurrence of rejection.
Most surgical series have been concerned with the influence of PHT on perioperative cardiovascular risk (1-3) and characteristically define PHT as a 20 mm Hg or 20% rise in mean arterial BP from preoperative readings. Using this definition, nearly all patients are exposed to PHT. Using Goldman's less stringent definition (2) (systolic BP Ͼ190 mm Hg and diastolic BP Ͼ100 mm Hg on two consecutive occasions), 42% of transplant recipients experienced PHT.
Ten percent of patients received antihypertensive therapy other than diltiazem after surgery, the majority (80%) continuing with ␤-blockade. Only 2% of patients had therapy introduced specifically for BP during the first 53 hr after surgery, most (80%) receiving short-acting dihydropyridine agents in the first instance. Eighty-three percent of patients commenced diltiazem after surgery, receiving their first dose 4 to 8 hr after transplantation with their first dose of cyclosporine. Although diltiazem was not being used for BP control, patients receiving diltiazem had lower BP levels (systolic 149 mm Hg versus 142 mm Hg, Pϭ0.03). This was explained by the fact that aboriginal patients (more of whom were hypertensive and diabetic) did not receive diltiazem in our study. After correcting for race, there were no differences in BP levels, with or without diltiazem.
Acute Rejection
Acute rejection occurred in 59% of patients (nϭ163). The median time to rejection was 12 days (95% confidence interval, 9 -18 days). Cox regression predictors for acute rejection are seen in Table 2 . A reduction in hazard rate of rejection was seen with the following: an increase in recipient age, DGF, use of triple-drug therapy with prednisolone, use of mycophenolate (not azathioprine), and an increase in HLA match (scored 0 to 6). In addition, an increase in hazard rate of rejection was seen with an increase in preoperative systolic blood pressure (SBP preop ) and standardized postperfusion systolic blood pressure (SBP pp ). Notably these hazard ratios are expressed per unit increase in mm Hg, meaning that a patient with an SBP pp of 200 mm Hg, compared with one with a mean of 150 mm Hg, experienced an increased hazard ratio of e cB , where eϭ2.71828 (the base of the natural loga- Figure 3 . The significant influence of the spline effect of SBP pp on the model is seen by a reduction in the Bayesian Information Criterion from 1675 to 1665; such a reduction (Ͼ10) indicates an overall better fit of the model (25) . None of the other covariate hazard ratios were significantly altered by incorporation of this spline effect into the model. Although the model for rejection was well specified according to standard criteria, both the Cox models demonstrated significant frailty (Pϭ0.02), indicating underlying patient heterogeneity. The revised hazard ratios using the frailty model are seen in Table 2 (Frailty HR); the overall effect of the hazard ratio changes suggests that the nonfrailty models underestimated the impact of the various covariate effects (18) .
DGF Requiring Dialysis
Twenty-seven percent of patients had DGF after renal transplantation (nϭ75) and required a mean of 2 weeks of dialysis before the onset of adequate graft function. An increase in odds/risk of DGF was seen with an increase in (i) donor age, (ii) recipient weight, and (iii) ischemic time and with nonwhite race, similar to previous studies. In addition, a decrease in odds/risk of DGF was seen with standardized postperfusion diastolic blood pressure (DBP pp ); that is, for each unit increase in DBP pp , the odds/risk of DGF decreased. A directly estimated risk ratio for DGF is provided in addition to the odds ratio (from logistic regression) for predictor variables, because the outcome (DGF) is not rare and hence, the odds ratios do not approximate the risk ratio (Table 3) . No significant interactions or nonlinearity of covariate effects was noted. The model predicting DGF demonstrated good discrimination (ROC areaϭ0.73) and calibration (goodnessof-fit test, Pϭ0.86).
Half (50%) of patients with SBP pp less than 120 mm Hg experienced DGF compared with 18% of patients with SBP pp controlled between 140 and 160 mm Hg. Hypertensive patients with SBP pp more than 170 mm Hg were also more likely to experience DGF (33%), although this difference did not reach significance (Pϭ0.12), possibly because of the small numbers of events.
Instrumental Variables Approach
The initial Cox model suggested DGF was paradoxically associated with a reduced risk of rejection in our population. Some of this effect may be explained by underdiagnosis of early rejection in patients with impaired graft function because of the reduction of clinical signs. Notably, the effect of DGF varied across BP groups, with significant effects confined to lower percentiles of SBP pp, (Fig. 3) . This suggests nonproportionality in the model, although this could not be firmly established (Pϭ0.16). It is also possible that impaired graft function was more likely attributed to ischemic injury than to a diagnosis of rejection in patients with the lowest BP levels. Using an instrumental variables approach in a logistic regression model, parameter estimates changed such that DGF was no longer a significant predictor of rejection (Pϭ0.197). However, neither the Hausman nor Smith-Blundell tests were significant (PϾ0.5), suggesting that conventional logistic regression parameter estimates were appropriate; that is, the predictor effect of DGF (for rejection) was not "endogenous." The exclusion of patients (nϭ13) who experienced DGF and were prescribed prednisolone did not alter these estimates (data not shown). DISCUSSION PHT is common in patients undergoing renal transplantation. This hardly seems surprising inasmuch as more than 80% of our patients had preexisting hypertension. Nonetheless the potential impact of this phenomenon on patient and graft outcomes should not be understated nor should its occurrence be taken as inevitable. PHT certainly contributes to patient morbidity and mortality (6) . Our study also suggests that PHT may also have deleterious effects on renal allograft outcomes.
The pattern of changes in BP observed in this study were essentially similar to those in patients undergoing vascular surgery. Patients with the greatest "preexisting" hypertension were more likely to experience a drop in their BP in response to induction and maintenance of anesthesia (Fig. 1) . This phenomenon was possibly accentuated in our population because the hypertensive dialysis patient is often kept at a lower "dry weight." With cessation of anesthesia, there was a rapid rebound in BP to preanesthetic levels. This propensity for labile BP in patients with high preoperative BPs should target such individuals for closer monitoring.
PHT is said to manifest within 30 min of the termination of surgery and resolve within 4 hr (1). However, unlike general surgery patients, many patients in our study continued to have elevated BP readings well beyond this period, suggesting additional factors way be present in transplant patients. Although BP may be an early sign of allograft rejection, it seems unlikely that occult rejection was the cause of PHT in this study. BP measurements during the first 53 hr preceded rejection (median, day 12), even though hypertensive patients had earlier rejection. In addition, conventional risk factors for acute rejection (such as increased PRA and poor HLA compatibility) did not influence the incidence of PHT.
Allograft dysfunction is said to be the main cause of late hypertension after renal transplantation (4, 5) . However, patients with DGF in our study had significantly lower mean diastolic BP, possibly reflecting the hypotensive etiology of DGF in some patients. Previous studies have found that hypotension before transplantation is associated with DGF (26). In our study, the mean diastolic BP exposure (DBP pp ) in the perioperative period (and not preoperative levels) was associated with DGF, suggesting that reperfusion pressure may be an important determinant of ischemic injury. It is for this reason (and the initiation of diltiazem) that antihypertensive therapy was routinely withheld immediately after transplant surgery at our center.
On the other hand, reperfusion injury may be influenced by systolic hypertension and contribute to a poor prognosis for patients with hypertension after ischemic injury (27) . The incidence of impaired graft function at 1 year is increased in patients with hypertension (5). In our study, patients with PHT seemed more likely to have DGF than normotensive individuals, although this did not reach significance. It is also possible that DGF may be too crude to detect allograft injury caused by hypertension. DGF seems to best reflect donor events or ischemic injury sustained during storage, transit, and surgery. Reperfusion injury may manifest much later as impaired graft function or as a risk for rejection, both of which have been associated with hypertension (5,28).
Cosio et al. (28) demonstrated that elevated BP levels after transplantation were significantly associated with more and earlier rejection. Our study suggests that BP control in the early phase of reperfusion may also influence allograft rejection, possibly by augmenting graft inflammation and injury. Without the protection of autoregulation or chronic accommodation and remodeling to the ambient hypertension present in most dialysis patients, naïve vessels exposed de novo to hypertension undergo an acute inflammatory response (11) . It is also possible that hypertension may be a marker for other rejection risk factors such as C-reactive protein, glucose intolerance, and increased circulating levels of tumor necrosis factor-␣ and interleukin 6 (29) . However, the effect of postoperative BP on acute rejection seen in our study was statistically independent of effects associated with preexisting hypertension. This raises the possibility of a direct effect of PHT in the early phases of tissue engraftment and the potential utility of BP interventions. Some studies have suggested that antihypertensive therapy may reduce acute rejection (28, 30) . Although our study failed to show benefit from the use of antihypertensive drugs (predominantly ␤-blockade), this may not reflect the true utility of perioperative antihypertensive therapy, because few patients in our study received medication specifically for the management of hypertension. In addition, the predominant use of short-acting vasodilators may have been potentially harmful.
Our small observational study is limited in its ability to define the precise role of early BP control in transplant outcomes. In addition, although statistically valid, the clinical significance of the interaction of BP and transplant outcomes is not established. Nonetheless, we document that hypertension is common in the early hours after renal transplantation and deserves greater attention, if only for the known risk of vascular events. More direct studies on the influence of hypertension on transplant outcomes are still required. The best intervention (if any) remains to be established. In the setting of impaired autoregulation, there may be a comparatively narrow window between ischemic and hypertensive injury within which to safely control BP. Although the prevention of PHT control has the potential to reduce allograft rejection, this needs to be balanced against the possible risk of DGF associated with reduction in perfusion pressure. 
